306 related articles for article (PubMed ID: 20547648)
1. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
[TBL] [Abstract][Full Text] [Related]
2. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
[TBL] [Abstract][Full Text] [Related]
3. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
[TBL] [Abstract][Full Text] [Related]
4. Liver Cancer in Tyrosinemia Type 1.
van Ginkel WG; Pennings JP; van Spronsen FJ
Adv Exp Med Biol; 2017; 959():101-109. PubMed ID: 28755188
[TBL] [Abstract][Full Text] [Related]
5. [Evolution of a case of tyrosinemia type I treated with NTBC].
Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
7. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
8. HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1.
Seda Neto J; Leite KM; Porta A; Fonseca EA; Feier FH; Pugliese R; Miura IK; Chapchap P; Porta G
Pediatr Blood Cancer; 2014 Sep; 61(9):1584-9. PubMed ID: 24852359
[TBL] [Abstract][Full Text] [Related]
9. Hereditary Tyrosinemia Type 1 in Turkey.
Aktuglu-Zeybek AC; Kiykim E; Cansever MS
Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
[TBL] [Abstract][Full Text] [Related]
10. Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis.
Cansever MS; Aktuğlu-Zeybek AC; Erim FB
Talanta; 2010 Mar; 80(5):1846-8. PubMed ID: 20152421
[TBL] [Abstract][Full Text] [Related]
11. Identification of NTBC metabolites in urine from patients with hereditary tyrosinemia type 1 using two different mass spectrometric platforms: triple stage quadrupole and LTQ-Orbitrap.
Herebian D; Lamshöft M; Mayatepek E; Spiekerkoetter U
Rapid Commun Mass Spectrom; 2010 Mar; 24(6):791-800. PubMed ID: 20187082
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment.
van Spronsen FJ; Bijleveld CM; van Maldegem BT; Wijburg FA
J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):90-3. PubMed ID: 15625434
[No Abstract] [Full Text] [Related]
13. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
Santra S; Baumann U
Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
[TBL] [Abstract][Full Text] [Related]
14. Late Development of Hepatocellular Carcinoma in Tyrosinemia Type 1 Despite Nitisinone (NTBC) Treatment.
Almuqbil M; Knoll J; Chinsky JM
J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):e73-e75. PubMed ID: 32141999
[No Abstract] [Full Text] [Related]
15. Nontransplant treatment of tyrosinemia.
Holme E; Lindstedt S
Clin Liver Dis; 2000 Nov; 4(4):805-14. PubMed ID: 11232358
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of primary liver cancer in children: an appraisal of experience.
Pham TH; Iqbal CW; Grams JM; Zarroug AE; Wall JC; Ishitani MB; Nagorney DM; Moir C
J Pediatr Surg; 2007 May; 42(5):834-9. PubMed ID: 17502194
[TBL] [Abstract][Full Text] [Related]
17. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.
Schauwvlieghe PP; Jaeken J; Kestelyn P; Claerhout I
Cornea; 2013 Jan; 32(1):91-4. PubMed ID: 22495034
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP.
van Ginkel WG; Gouw AS; van der Jagt EJ; de Jong KP; Verkade HJ; van Spronsen FJ
Pediatrics; 2015 Mar; 135(3):e749-52. PubMed ID: 25667247
[TBL] [Abstract][Full Text] [Related]
20. NTBC and Correction of Renal Dysfunction.
Maiorana A; Dionisi-Vici C
Adv Exp Med Biol; 2017; 959():93-100. PubMed ID: 28755187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
